Value of [¹⁸F]-FDG positron emission tomography in patients with recurrent glioblastoma receiving bevacizumab.

ABSTRACT:

Background

Treatment of recurrent glioblastoma (GBM) with bevacizumab can induce MRI changes that confound the determination of progression. We sought to determine the value of [¹⁸F]-fluorodeoxyglucose (FDG) positron emission tomography (PET) in GBM patients receiving bevacizumab at the time of suspected progression and, thereby, its utility as a potential prognostic adjunct in progressive disease.

Methods

This retrospective study included patients who underwent brain FDG PET within 4 weeks of receiving bevacizumab for recurrent GBM with suspected progression. Volumes-of-interest were placed over the reference lesion with measurement of maximum standardized uptake value (SUV_max), peak standardized uptake value (SUV_peak), metabolic tumor volum

SUBMITTER: Graham MS 

PROVIDER: S-EPMC7236386 | biostudies-literature | 2020 Jan-Dec

REPOSITORIES: biostudies-literature